DMSO stock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Cristalino [kɾistaˈlino] ("crystalline"): aged tequila that has been filtered to remove its color before bottling, similar to chill filtering of whisky Rosa ("pink"): a young version of the spirit "lightly aged in red wine barrels"
== Occurrence == The purine nucleotide cycle occurs in the cytosol (intracellular fluid) of the sarcoplasm of skeletal muscle, and in the myocyte's cytosolic compartment of the cytoplasm of cardiac and smooth muscle. The cycle occurs when ATP reservoirs run low (ADP > ATP), such as strenuous exercise, fasting or starvation. Proteins catabolize into amino acids, and amino acids are precursors for purines, nucleotides and nucleosides which are used in the purine nucleotide cycle. The amino acid glutamate is used to neutralize the ammonia produced when AMP is converted into IMP. Another amino acid, aspartate, is used along with IMP to produce S-AMP in the cycle. Skeletal muscle contains amino acids for use in catabolism, known as the free amino acid pool; however, inadequate carbohydrate supply and/or strenuous exercise requires protein catabolism to sustain the free amino acids. When the phosphagen system (ATP-PCr) has been depleted of phosphocreatine (creatine phosphate), the purine nucleotide cycle also helps to sustain the myokinase reaction by reducing accumulation of AMP produced after muscle contraction in the below reaction. During muscle contraction:
== History == On 18 January 1839, the British East India Company landed Royal Marines at Aden. Their aims were to establish a supply port and stop attacks by Arab pirates against British shipping to India. The British Government thereafter considered Aden to be an important settlement due to its location, as the Royal Navy could easily access the port for resupply and repairs. Later, British influence extended progressively into the hinterland, both west and east, leading to the establishment of the Aden Protectorate.
Sources: en.wikipedia.org
== Advantages == There are many advantages to using a proton beam over an electron beam. There is less crystal charging from Bremsstrahlung radiation, although there is some from the emission of Auger electrons, and there is significantly less than if the primary beam was itself an electron beam. Because of the higher mass of protons relative to electrons, there is less lateral deflection of the beam; this is important for proton beam writing applications.
== Involvement in elections == F2 Logistics has been involved in the distribution of election equipment and paraphernalia in the Philippines. It was the national courier of the Commission on Elections (COMELEC) for the 2018 barangay and Sangguniang Kabataan elections. F2 Logistics has also secured two of four delivery contracts for the 2019 elections. The company has also secured a distribution deal with the COMELEC for the 2022 national elections. The deal has been questioned by Senator Leila de Lima, the National Citizens' Movement for Free Elections, and other civic groups, due to F2 Logistics chairman Dennis Uy's association with incumbent President Rodrigo Duterte, believing that the company has a conflict of interest. Among the company's incorporators include the Duterte administration's executive secretary Salvador Medialdea. The COMELEC dispute the allegation, saying that the awarding of the associated contract was done through public bidding and that F2 Logistics was awarded the deal on the merit that the company offered the lowest responsive bid.
Muslims, India's largest religious minority, have contributed significantly to a synthetic Indo-Islamic religious culture. Sufism, the heterodox mystical movement in Islam found receptiveness among adherents of the medieval regional Shaivite and Vaishnavite traditions of Bhakti. Sikh gurdwaras and Sufi dargahs often attract both visitors and worshippers from other religions. India has monastic traditions such as that of Jain ascetics some of whom practice an extreme form of nonviolence (ahimsa) and Buddhist communities that have preserved ancient styles of meditations. This religious diversity coexists with religious endogamy—people rarely marry outside their faith. There is also religious segregation in housing—religious groups cluster by choice or necessity. Thus, India's religious picture has both rich intermixing and clear divisions.
Founded in 1896 by Fritz Hoffmann-La Roche, the company was known early on for producing various vitamin preparations and derivatives. In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon. During the Second World War, Roche collaborated with the Nazi regime in Germany and used forced labour in its German and Polish-based factories. It also moved all its Jewish employees to the United States to save them from Nazi attention. In 1957, Hoffmann-La Roche introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members). It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid. Originally, it had been intended to create a more efficient drug at combatting tuberculosis. Iproniazid, however, was revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects. In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large dioxin contamination. In 1982, the United States arm of the company acquired Biomedical Reference Laboratories for US$163.5 million. That company dated from the late 1960s, and was located in Burlington, North Carolina. That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc. in Burlington.
Sources: en.wikipedia.org
== History == Methaqualone was first synthesized in India in 1951 by Indra Kishore Kacker and Syed Husain Zaheer, who were conducting research on finding new antimalarial medications. In 1962, methaqualone was patented in the United States by Wallace and Tiernan. By 1965, it was the most commonly prescribed sedative in Britain, where it has been sold legally under the names Malsed, Malsedin, and Renoval. In 1965, a methaqualone/antihistamine combination was sold as the sedative drug Mandrax in Europe, by Roussel Laboratories (now part of Sanofi S.A.). In 1972, it was the sixth-bestselling sedative in the US, where it was legal under the brand name Quaalude. Sold in the United States under the brand name Quaalude, methaqualone was moved to Schedule I in 1984 after prescription controls failed to curb diversion. Quaalude in the United States was originally manufactured in 1965 by the pharmaceutical firm William H. Rorer, Inc., based in Fort Washington, Pennsylvania. The drug name "Quaalude" is a portmanteau, combining the words "quiet interlude" and shared a stylistic reference to another drug marketed by the firm, Maalox. In 1978, Rorer sold the rights to manufacture Quaalude to the Lemmon Company of Sellersville, Pennsylvania. At that time, Rorer chairman John Eckman commented on Quaalude's bad reputation stemming from illegal manufacture and use of methaqualone, and illegal sale and use of legally prescribed Quaalude: "Quaalude accounted for less than 2% of our sales, but created 98% of our headaches." Both companies still regarded Quaalude as an excellent sleeping drug.
Complete androgen insensitivity syndrome (CAIS) is an AIS condition that results in the complete inability of the cell to respond to androgens. As such, the insensitivity to androgens is only clinically significant when it occurs in individuals who are exposed to significant amounts of testosterone at some point in their lives. The unresponsiveness of the cell to the presence of androgenic hormones prevents the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does allow, without significant impairment, female genital and sexual development in those with the condition. All human fetuses begin fetal development looking similar, with both the Müllerian duct system (female) and the Wolffian duct system (male) developing. Sex differentiation begins with the gonads, which in XX individuals become ovaries, and in XY individuals (including those with CAIS) typically become testicles due to the presence of the Y chromosome. It is at the seventh week of gestation that the bodies of non-CAIS individuals with the XY karyotype begin their masculinization: i.e., the Wolffian duct system is promoted and the Müllerian duct system is suppressed (the reverse happens with typically developing females). This process is triggered by androgens produced by the testicles.
Fast protein liquid chromatography (FPLC), is a form of liquid chromatography that is often used to analyze or purify mixtures of proteins. As in other forms of chromatography, separation is possible because the different components of a mixture have different affinities for two materials, a moving fluid (the "mobile phase") and a porous solid (the stationary phase). In FPLC the mobile phase is an aqueous solution, or "buffer". The buffer flow rate is controlled by a positive-displacement pump and is normally kept constant, while the composition of the buffer can be varied by drawing fluids in different proportions from two or more external reservoirs. The stationary phase is a resin composed of beads, usually of cross-linked agarose, packed into a cylindrical glass or plastic column. FPLC resins are available in a wide range of bead sizes and surface ligands depending on the application.
=== Timeline of events === In 2012 a large shipment of cocaine was stolen by the Turtle clan in the Port of Antwerp. This eventually led to a gang war amongst multiple criminal organisations which the Dutch and Belgian media outlets described as the Mocro-War. From this point on, many people from Dutch- and Belgian-Moroccan descent were killed in various shootings across Belgium, the Netherlands, Spain, Morocco, and Suriname. Ridouan Taghi became a prominent figure within the Moroccan mafia, who had a large share in the European cocaine trade, and he was also responsible for a lot of gangland killings across Europe. He is currently jailed in a maximum security prison in the Netherlands awaiting his trial. His right-hand man Saïd Razzouki was arrested in Bogotá, Colombia, extradited to the Netherlands, and in February 2024 was sentenced to life imprisonment for his role in ten murders. In Antwerp, the term Borgerokko-Maffia is often used due to the large impact of the illegal economy in the district of Borgerhout. The trade of this illegal economy has its origins in the Moroccan street gangs of Antwerp and Amsterdam, which is described in the 2014 published book Borgerokko Maffia by Raf Sauviller, and also in the book Mocro Maffia by criminologist Martijn Schrijver. The Moroccan mafia has appeared in most of the large Belgian and Dutch cities including Antwerp, Brussels, Amsterdam, Rotterdam, Utrecht and Almere.
== Overview == The SEA group belongs to the N,S-acyl shift systems because its reactivity is dictated by the intramolecular nucleophilic addition of one SEA thiol group on the C-terminal carbonyl group of the peptide segment. This results in the migration of the peptide chain from the nitrogen to the sulfur. The overall process of SEA native peptide ligation involves first an N,S-acyl shift for in in situ formation of a peptide thioester, and later on, after thiol-thioester exchange, an S,N-acyl shift for formation of the peptide bond.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.